Intellia Therapeutics Inc
NTLAHealthcare|Biotechnology|USA
$14.21
-1.23 (-7.99%)
Tangible Book
$5.16
Upcoming Data Readouts (4)
Jul 2027
Est. completion
Dec 2027
Est. completion
P3Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
NCT06128629n=1,200
Aug 2034
Est. completion
P1P2Hemophilia B
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
NCT06379789n=130
Mar 2038
Est. completion
Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001
NCT05697861n=72
Awaiting Results (2)
Trials past primary completion date but still active — data readout may be imminent.
Feb 2026
P3
HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)
NCT06634420